Drug Discovery

Sanofi establishes mRNA Center of Excellence to accelerate Covid-19 vaccines development

Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines.

AbbVie to acquire TeneoOne and multiple myeloma drug from Teneobio

AbbVie is set to acquire Teneobio affiliate TeneoOne and its lead drug candidate TNB-383B, which is being developed to treat relapsed or refractory multiple myeloma (R/R MM).

ViiV Healthcare, Halozyme partner to develop HIV medicines

ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV.

Arrowhead, Horizon sign collaboration deal for RNAi therapeutic development

Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH.

MorphoSys agrees to acquire Constellation Pharmaceuticals for $1.7bn

German company MorphoSys has signed a definitive agreement to acquire US-based Constellation Pharmaceuticals for approximately $1.7bn.

Amgen, Kyowa Kirin partner to develop antibody for atopic dermatitis

Amgen has signed an agreement with Japanese pharmaceutical firm Kyowa Kirin to jointly develop and commercialise Phase III-ready antibody for treating atopic dermatitis.

Pieris and Genentech to develop respiratory and ophthalmology therapies

Biotechnology company Pieris Pharmaceuticals has signed a multi-programme research collaboration and licence agreement with Roche Group subsidiary Genentech.

Exscientia expands AI-based drug discovery alliance with BMS

Exscientia and Bristol-Myers Squibb agree to leverage AI to discover drug candidates for various diseases.

Lilly, MiNA Therapeutics partner to develop new drug candidates

Eli Lilly and Company and MiNA Therapeutics are set to develop new drug candidates as part of a global research collaboration.